In women with breast cancer, cardiolipin correlated positively with myocardial fibrosis and oleic acid content in red blood cells correlated positively with myocardial edema after 1 cycle of anthracycline chemotherapy.
Cohort (n=14)
Does 1 cycle of anthracycline chemotherapy induce myocardial injury and blood lipidome changes in women with breast cancer?
Blood lipidomic changes, specifically cardiolipin and red blood cell oleic acid content, correlate with early CMR signs of myocardial injury following anthracycline chemotherapy.
Background: Anthracycline chemotherapy (AC) leads to cardiotoxicity in many patients with breast cancer by inducing inner mitochondrial damage and disrupting the electron transport chain. It is unclear why some, but not all, women who undergo AC develop chronic cardiac dysfunction. Objectives: The aim of this prospective feasibility study was to determine accrual rate and estimate the effect size of 1 cycle of AC on myocardial injury and blood lipidome changes in women with breast cancer. Methods: Fourteen women with breast cancer planning to undergo AC enrolled and underwent cardiac magnetic resonance (CMR) imaging and blood sampling across 2 visits, before and after any 1 cycle of AC in the treatment regimen. Fatty acid composition of red blood cells (RBCs) and cardiolipin (CL) in peripheral blood mononuclear cells were measured. Exploratory analyses were conducted. Results: CL correlated positively with myocardial fibrosis, and OA content in RBCs correlated positively with myocardial edema. Conclusions: CL against AC.This trial was registered at clinicaltrials.gov as NCT03961685.
Marris et al. (Thu,) conducted a cohort in Breast cancer (n=14). Anthracycline chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Accrual rate and effect size of 1 cycle of anthracycline chemotherapy on myocardial injury and blood lipidome changes. In women with breast cancer, cardiolipin correlated positively with myocardial fibrosis and oleic acid content in red blood cells correlated positively with myocardial edema after 1 cycle of anthracycline chemotherapy.